4Twenteezs with Pablo Zuanic

Renowned analyst Pablo Zuanic conducts insightful interviews with key figures in the cannabis and hemp industry, helping investors better understand the dynamic sectoral landscape and gain first-hand knowledge of the various operators.

Zuanic & Associates is a boutique equity research, consulting, and advisory firm covering the emerging consumer sectors. Led by renowned Wall Street analyst Pablo Zuanic, the firm covers companies in North America and overseas, publishing both thematic and stock-specific research. The firm’s publications are often covered by the business wires, trade publications, and social media.

Follow us on

http://zuanicassociates.com

pablo.zuanic@zuanicgoup.com in

X https://x.com/420Odysseus

https://www.linkedin.com/company/zuanic-associates-llc

Disclaimer: The content presented in this video clip is an integral part of Zuanic & Associates’ due diligence and research process. The views and opinions expressed by the speakers are solely their own and do not necessarily represent the views or opinions of Zuanic & Associates, its affiliates, or its employees. Zuanic & Associates may have current or future business relationships with the companies or individuals mentioned in this video; however, any such relationships are not intended to influence the content presented herein. This video is provided solely for educational and informational purposes. This video is not intended as investment advice, nor should it be construed as a recommendation to engage in any investment activity. Investors are encouraged to conduct their own thorough research and analysis and to seek advice from qualified financial advisors before making any investment decisions. The information contained in this video should be used as a supplementary tool, not as the sole basis for any investment decision.

Den här podcasten är hämtad från ett öppet RSS-flöde och publiceras inte av Podme. Den kan innehålla reklam.

Avsnitt(72)

Latest Trends & Innovation in Vaping

Note: This call is relevant to all companies competing in the cannabis vaping space (and competing formats) as well as to companies supplying the vaping hardware, and to investors that follow the spac...

28 Juni 20241h 7min

The Start of Ohio Cannabis Rec Sales

Speakers:Trent Woloveck, Chief Strategy Director, Jushi HoldingsEric Offenberger, CEO, Vext ScienceJeremy Unruh, SVP Public and Regulatory Affairs, PharmaCannHosted By:Pablo Zuanic, Senior Analyst#can...

6 Juni 20241h

The First 45 Days of Germany's Pillar 1

Germany's MMJ market has seen explosive growth since April 1st (change in narcotics law, as part of Pillar I). Hence, this Zoom call with the largest online pharmacy, one of the largest clinic network...

16 Maj 20241h 10min

Looking beyond Meme | Spaces with Zach George, CEO of SNDL

SNDL is a public company whose shares are traded on Nasdaq under the symbol "SNDL." SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquo...

16 Maj 202451min

Path to move marijuana from Schedule I to III : In depth discussion with legal scholar, Shane Pennington

Pablo Zuanic hosted legal scholar Shane Pennington from Porter Wright Morris & Arthur to discuss the various cannabis RESCHEDULING scenarios. The podcast is sponsored by NewLake Capital Partners. Thei...

13 Maj 20241h 15min

California, a case study for the future U.S. cannabis market?

California PanelLaurie Holcomb, CEO of Gold FloraArden Lee, CFO of West Coast CureWesley Hein, President of Cabbabis Dist Assoc, Mammoth DistributionGold Flora is a California-licensed premium cannabi...

8 Maj 202458min

Straight Talk with Irwin Simon | CEO of Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin A...

6 Maj 202438min

Rescheduling of Cannabis with Charlie Bachtell | CEO Cresco Labs

We discuss the latest news leak from the DEA regarding the rescheduling of Cannabis from an S1 to S3 drug. This news opens up a wealth of opportunities for the industry. Pablo and Charlie navigate the...

1 Maj 202442min